Last update 23 Jan 2025

Lilly SA

Subsidiary Company|
1953|
Spain
|
www.lilly.es

Overview

Tags

Nervous System Diseases
Other Diseases
Small molecule drug

Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Disease DomainCount
Nervous System Diseases1
Top 5 Drug TypeCount
Small molecule drug2
Top 5 TargetCount
NET(Norepinephrine transporter)1
AMPA receptor x GluR-5 x Kainate receptor1

Related

2
Drugs associated with Lilly SA
Atomoxetine Hydrochloride
Target
NET
Mechanism
NET inhibitors
Active Org.
Eli Lilly Australia Pty Ltd. [+3]
Originator Org.
Eli Lilly & Co.Eli Lilly & Co.
Active Indication
Attention Deficit Disorder With Hyperactivity
Inactive Indication
Alzheimer Disease [+11]
Drug Highest PhaseApproved
First Approval Ctry. / Loc.
US
First Approval Date26 Nov 2002
Dasolampanel
Target
AMPA receptor x GluR-5 x Kainate receptor
Mechanism
AMPA receptor antagonists [+2]
Active Org.
Lilly SA
Originator Org.
Eli Lilly & Co.Eli Lilly & Co.
Active Indication
Pain
Inactive Indication
Diabetic peripheral neuropathic pain [+2]
Drug Highest PhasePreclinical
First Approval Ctry. / Loc.-
First Approval Date-
33
Clinical Trials associated with Lilly SA
EUCTR2012-003201-96-ES
/ Not yet recruitingNot Applicable
A Single-Arm, Multicenter, Open-Label, Phase 2 Study ofGemcitabine-Cisplatin Chemotherapy Plus Necitumumab(IMC-11F8) in the First-Line Treatment of Patients WithStage IV Squamous Non-Small Cell Lung Cancer (NSCLC)
EUCTR2010-022674-14-ES
/ Unknown statusNot Applicable
Estudio en fase 2, abierto, multicéntrico y aleatorizado para evaluar la seguridad y la eficacia de cisplatino y pemetrexed con o sin cixutumumab como tratamiento de primera línea en pacientes con carcinoma de pulmón no microcítico avanzado, de histología no escamosaAn Open-label, Multicenter, Randomized Phase 2 Study Evaluating the Safety and Efficacy of Cisplatin and Pemetrexed With or Without Cixutumumab as First Line Therapy in Patients with Advanced Nonsquamous Non Small Cell Lung Carcinoma
EUCTR2010-020726-18-ES
/ Not yet recruitingNot Applicable
Estudio Abierto de Seguridad a Largo Plazo de LY2216684 12 a 18 mg Una Vez al Día como Tratamiento Adyuvante para Pacientes con Trastorno Depresivo Mayor con Respuesta Parcial al Tratamiento con un Inhibidor Selectivo de la Recaptación de SerotoninaLong-Term, Open-Label, Safety Study of LY2216684 12 to 18 mg Once Daily as Adjunctive Treatment for Patients with Major Depressive Disorder Who are Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment - LNBO
100 Clinical Results associated with Lilly SA
Login to view more data
0 Patents (Medical) associated with Lilly SA
Login to view more data
100 Deals associated with Lilly SA
Login to view more data
100 Translational Medicine associated with Lilly SA
Login to view more data

Corporation Tree

Boost your research with our corporation tree data.
login
or
view full example data
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 23 Jan 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Preclinical
1
1
Approved
Login to view more data

Current Projects

Drug(Targets)IndicationsGlobal Highest Phase
Atomoxetine Hydrochloride
 ( NET )		Attention Deficit Disorder With Hyperactivity
More
Approved
Dasolampanel
 ( AMPA receptor x GluR-5 x Kainate receptor )		Pain
More
Preclinical
Login to view more data

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
login
or
view full example data
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
login
or
view full example data
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
login
or
view full example data
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
login
or
view full example data
Unearth financing trends to validate and advance investment opportunities.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free